A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis

Diabetes Research and Clinical Practice

Volumn 91, Issue 1, 2011, Pages 72-79

  Cho, Jae Min ^a   Jang, Hye Won ^a   Cheon, Hwanju ^a   Jeong, Yeon Taek ^a   Kim, Do Hoon ^a   Lim, Yu Mi ^a   Choi, Song Hyen ^b   Yang, Eun Kyoung ^b   Shin, Chang Yell ^b   Son, Moon Ho ^b   Kim, Soon Hoe ^b   Kim, Heung Jae ^b   Lee, Myung Shik ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

Author keywords

Cell; Diabetes; Dipeptidyl peptidase IV; Glucagon like peptide 1

Indexed keywords

DA 1229; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; TRANSCRIPTION FACTOR PDX 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL REGENERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; LONG TERM CARE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; STREPTOZOCIN DIABETES;

ANIMALS; BLOOD GLUCOSE; CELL COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SIZE; DIABETES MELLITUS, EXPERIMENTAL; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; HOMEODOMAIN PROTEINS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED C57BL; PIPERAZINES; REGENERATION; STREPTOZOCIN; TRANS-ACTIVATORS;

EID: 78650584379     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.10.012     Document Type: Article

References (34)

1. Atkinson M.A., Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001, 358:221-229.
2. Gerich J.E. Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology. Eur J Clin Invest 2002, 32:S46-53.
3. Kaiser N., Leibowitz G., Nesher R. Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2003, 16:5-22.
4. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
5. Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999, 48:2270-2276.
6. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
7. Mest H.J., Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005, 48:616-620.
8. Mu J., Woods J., Zhou Y.P., Roy R.S., Li Z., Zycband E., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006, 55:1695-1704.
9. Ahren B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 2007, 30:1344-1350.
10. Pospisilik J.A., Martin J., Doty T., Ehses J.A., Pamir N., Lynn F.C., et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003, 52:741-750.
11. Kim H.J., Kim H.D., Kwak W.Y., Shin C.Y., Min J.P., Yoon T.H., et al. Characteristics of DA-1229, a novel, highly potent and selective DPP4 inhibitor [Abstract]. Diabetes 2008, 57:2611-PO.
12. Ahn J.H., Kim J.A., Kim H.M., Kwon H.M., Huh S.C., Rhee S.D., et al. Synthesis and evaluation of pyrazolidine derivatives as dipeptidyl peptidase IV (DP-IV) inhibitors. Bioorg Med Chem Lett 2005, 15:1337-1340.
13. Kim Y.H., Kim S., Kim K.A., Yagita H., Kayagaki N., Kim K.W., et al. Apoptosis of pancreatic beta-cells detected in accelerated diabetes of NOD mice: no role of Fas-Fas ligand interaction in autoimmune diabetes. Eur J Immunol 1999, 29:455-465.
14. Weaver C.V., Sorenson R.L., Kaung H.C. Immunocytochemical localization of insulin-immunoreactive cells in the pancreatic ducts of rats treated with trypsin inhibitor. Diabetologia 1985, 28:781-785.
15. Weibel E.R. Sterologic methods. Practical methods for biologic morphometry 1978, 101-161. Academic Press, London. E.R. Weibel (Ed.).
16. Jung H.S., Chung K.W., Won Kim J., Kim J., Komatsu M., Tanaka K., et al. Loss of autophagy diminishes pancreatic beta cell mass and function with resultant hyperglycemia. Cell Metab 2008, 8:318-324.
17. Bouwens L., Pipeleers D.G. Extra-insular beta cells associated with ductules are frequent in adult human pancreas. Diabetologia 1998, 41:629-633.
18. Thorkildsen C., Neve S., Larsen B.D., Meier E., Petersen J.S. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther 2003, 307:490-496.
19. Sorhede Winzell M., Ahren B. Glucagon-like peptide-1 and islet lipolysis. Horm Metab Res 2004, 36:795-803.
20. Soltani N., Kumar M., Glinka Y., Prud'homme G.J., Wang Q. In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes. Gene Ther 2007, 14:981-988.
21. Liu Z., Habener J.F. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 2008, 283:8723-8735.
22. Li Y., Cao X., Li L.-X., Brunbaker P.L., Edlund H., Drucker D.J. β-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 2005, 54:482-491.
23. Drucker D.J. Minireview: the glucagon-like peptides. Endocrinology 2001, 142:521-527.
24. Dupre J., Behme M.T., Hramiak I.M., McFarlane P., Williamson M.P., Zabel P., et al. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 1995, 44:626-630.
25. Gutniak M., Orskov C., Holst J.J., Ahren B., Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992, 326:1316-1322.
26. Creutzfeldt W.O., Kleine N., Willms B., Orskov C., Holst J.J., Nauck M.A. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 1996, 19:580-586.
27. Prentki M., Nolan C.J. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006, 116:1802-1812.
28. Komada S., Toyonaga T., Knodo T., Matsumoto K., Tsuruzoe K., Kawashima J., et al. Enhanced expression of PDX-1 and Ngn3 by exendin-4 during β-cell regeneration in STZ-treated mice. Biochem Biophy Res Com 2005, 327:1170-1178.
29. Li Y., Hansotia T., Yusta B., Ris F., Halban P.A., Drucker D.J. Glucagon-like peptide-1 receptor signaling modulates β-cell apoptosis. J Biol Chem 2003, 278:471-478.
30. de Koning E.J., Bonner-Weir S., Rabelink T.J. Preservation of beta-cell function by targeting beta-cell mass. Trends Pharmacol Sci 2008, 29:218-227.
31. Sherry N.A., Chen W., Kushner J.A., Glandt M., Tang Q., Tsai S., et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 2007, 148:5136-5144.
32. Ogawa N., List J.F., Habener J.F., Maki T. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 2004, 53:1700-1705.
33. Tian L., Gao J., Hao J., Zhang Y., Yi H.T., O'Brien D., et al. Reversal of new-onset diabetes through modulating inflammation and stimulating β-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology 2010, 151:3049-3060.
34. Pugazhenthi U., Velmurugan K., Tran A., Mahaffey G., Pugazhenthi S. Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients. Diabetologia 2010, 53:2357-2368.